MDGL — Madrigal Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$538.71
-$1.32 (-0.24%)
Madrigal Pharmaceuticals Inc (MDGL) is a biotechnology company listed on NASDAQ. It is led by William J. Sibold, based in Four Tower Bridge, West Conshohocken, PA, United States, 19428, with about 915 employees. Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Latest reported MDGL revenue for 2025-09-30 was $287.3M. Net income was -$229.7M. Revenue was up 35.0% from 2025-06-30 to 2025-09-30. MDGL currently screens at market cap $11.56B.
Use this MDGL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MDGL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MDGL SEC filings page. Lician reads the product cache first so this HTML stays unique to Madrigal Pharmaceuticals Inc even when a live quote feed is slow.
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
MDGL Key Statistics
Market Cap
$11.56B
Volume
188,484
Previous Close
$511.97
Day Range
$506.29 – $523.35
P/B Ratio
21.27
EPS
-$21.90
Revenue
$180.13M
Net Income
-$465.89M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-258.6%
Employees
915
MDGL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $180.13M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$465.89M | -$373.63M | -$295.35M |
| EPS (Diluted) | -$21.90 | -$5.68 | -$4.98 |
Total Assets
$1.04B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$100.02M
Operating Cash Flow
-$455.57M
Free Cash Flow
$0.00
Madrigal Pharmaceuticals Inc Company Information
- CEO, President & Director
- William J. Sibold
- Headquarters
- Four Tower Bridge, West Conshohocken, PA, United States, 19428
- Website
- www.madrigalpharma.com
- Phone
- 267 824 2827
- IPO / Founded
- 2007-02-06
- Sector
- Healthcare
- Industry
- Biotechnology